Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Other: No intervention
- Registration Number
- NCT04498156
- Lead Sponsor
- Bayer
- Brief Summary
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians know about the different treatment options available; and how they use this knowledge to treat their patients successfully. Additionally, researchers want to gather information about patient's awareness of their disease and which criteria they consider important for their treatment of the disease.
The study will survey a total of 150 patients with type 2 diabetes: 50 patients with mild CKD; 50 patients with moderate CKD; and 50 patients with severe CKD. Patients eligible for this study can be male or female and should be at least 18 years old. In addition, a total of 150 physicians will be surveyed. Physicians eligible for this study may be general practitioners, endocrinologist, or nephrologists.
- Detailed Description
The primary objective in this study is to assess the awareness, values and preferences of patients and physicians with respect to the risks, consequences and management of chronic kidney disease (CKD) in patients with type 2 diabetes.
Secondary objectives aim to assess awareness of available CKD treatments, referral tools and communication between patients and physicians.
Both patients and physicians will complete a survey that consists of various questions regarding the knowledge of disease, values and treatments, patient-physician interaction, physician referral tools and disease risk management.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
-
For patient cohort:
- Diagnosis of type 2 diabetes
- eGFR < 60 ml/min per 1.73 m2 (measured within the last year) OR eGFR ≥ 60 ml/min per 1.73 m2 and uACR ≥ 2 (measured within the last year)
- No documented non-diabetic etiology for renal disease
-
For physician cohort:
- Licensed general practitioner, endocrinologist or nephrologist
- Currently providing care for patients with chronic kidney disease and type 2 diabetes
- Patients with chronic kidney disease and type 2 diabetes who are physicians
- Physicians with chronic kidney disease and type 2 diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description CKD-Patients No intervention Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD) Physicians treating CKD No intervention Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
- Primary Outcome Measures
Name Time Method Awareness of chronic kidney disease in T2D 1 day Awareness will be summarized descriptively based on various survey questions.
Values regarding chronic kidney disease in T2D 1 day Values regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
Preferences regarding chronic kidney disease in T2D 1 day Preferences regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
- Secondary Outcome Measures
Name Time Method Time point of communicated CKD diagnosis 1 day Awareness of available treatments for chronic kidney disease in T2D 1 day Awareness of available treatments will be summarized descriptively based on various survey questions.
Physician awareness of available referral tools for the management of chronic kidney disease in T2D 1 day Physician cohort only. Referral tools may comprise of various standard guidelines (e.g. KidneyWise, KDIGO guidelines, Diabetes Canada guidelines). A higher number of referral tools known by physicians indicates a better awareness of CKD referral tools.
Trial Locations
- Locations (1)
Many Facilities
🇨🇦Multiple Locations, Canada